NCT01494805View on ClinicalTrials.gov

Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

May 31, 2017

Study Completion Date

August 31, 2017

Conditions
Macular DegenerationAge-related MaculopathiesAge-related MaculopathyMaculopathies,Age-relatedMaculopathy,Age-relatedRetinal DegenerationRetinal NeovascularizationEye Diseases
Interventions
BIOLOGICAL

rAAV.sFlt-1

1 x 10\^10 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection

BIOLOGICAL

rAAV.sFlt-1

1 x 10\^11 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection

OTHER

Control (ranibizumab alone)

Patients will not receive rAAV.sFlt-1, but will be eligible for retreatment with ranibizumab (Lucentis).

Trial Locations (1)

6009

Lions Eye Institute, Nedlands

Sponsors
All Listed Sponsors
collaborator

Adverum Biotechnologies, Inc.

INDUSTRY

lead

Lions Eye Institute, Perth, Western Australia

OTHER

NCT01494805 - Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter